Zacks Investment Research
19 Jun 2026, 15:36 UTC · 2h ago
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 15:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA has cleared the investigational new drug (IND) application for Beam Therapeutics' BEAM-304 gene-editing therapy for phenylketonuria (PKU). — FDA clearance is a critical regulatory milestone that allows the company to move into human clinical trials, reducing binary risk for the drug candidate.
+0.60Beam Therapeutics plans to initiate a phase I/II open-label clinical study to assess the safety, tolerability, and efficacy of BEAM-304 in PKU patients. — The transition to clinical trials provides a clear path toward potential commercialization in a market with no approved curative treatments.
+0.30Which stocks this story touches
FDA clearance of IND application for BEAM-304 and a 5% stock price increase.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
